vs

Side-by-side financial comparison of ACV Auctions Inc. (ACVA) and CareDx, Inc. (CDNA). Click either name above to swap in a different company.

ACV Auctions Inc. is the larger business by last-quarter revenue ($183.6M vs $117.7M, roughly 1.6× CareDx, Inc.). On growth, CareDx, Inc. posted the faster year-over-year revenue change (39.0% vs 15.1%). CareDx, Inc. produced more free cash flow last quarter ($514.0K vs $-14.7M). Over the past eight quarters, CareDx, Inc.'s revenue compounded faster (12.9% CAGR vs 12.3%).

ACV Auctions Inc. operates a leading digital wholesale vehicle auction platform serving automotive dealers across the U.S. and Canada. It offers end-to-end services including transparent vehicle inspections, secure payment processing, and logistics support, enabling efficient trading of used vehicles between registered wholesale buyers and sellers.

CareDx, Inc. is a leading precision medicine company dedicated to organ transplant patient care. It develops and commercializes diagnostic tests for rejection surveillance, digital health management tools, and supportive clinical services, catering to transplant clinicians, patients, and healthcare systems across North America and European core markets.

ACVA vs CDNA — Head-to-Head

Bigger by revenue
ACVA
ACVA
1.6× larger
ACVA
$183.6M
$117.7M
CDNA
Growing faster (revenue YoY)
CDNA
CDNA
+23.9% gap
CDNA
39.0%
15.1%
ACVA
More free cash flow
CDNA
CDNA
$15.2M more FCF
CDNA
$514.0K
$-14.7M
ACVA
Faster 2-yr revenue CAGR
CDNA
CDNA
Annualised
CDNA
12.9%
12.3%
ACVA

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ACVA
ACVA
CDNA
CDNA
Revenue
$183.6M
$117.7M
Net Profit
$2.8M
Gross Margin
Operating Margin
-9.7%
1.0%
Net Margin
2.4%
Revenue YoY
15.1%
39.0%
Net Profit YoY
EPS (diluted)
$-0.12
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACVA
ACVA
CDNA
CDNA
Q1 26
$117.7M
Q4 25
$183.6M
$108.4M
Q3 25
$199.6M
$100.1M
Q2 25
$193.7M
$86.7M
Q1 25
$182.7M
$84.7M
Q4 24
$159.5M
$86.6M
Q3 24
$171.3M
$82.9M
Q2 24
$160.6M
$92.3M
Net Profit
ACVA
ACVA
CDNA
CDNA
Q1 26
$2.8M
Q4 25
$-4.1M
Q3 25
$-24.5M
$1.7M
Q2 25
$-7.3M
$-8.6M
Q1 25
$-14.8M
$-10.4M
Q4 24
$87.7M
Q3 24
$-16.0M
$-10.6M
Q2 24
$-17.1M
$-4.6M
Operating Margin
ACVA
ACVA
CDNA
CDNA
Q1 26
1.0%
Q4 25
-9.7%
-5.6%
Q3 25
-11.9%
-0.2%
Q2 25
-3.7%
-12.8%
Q1 25
-7.9%
-15.8%
Q4 24
-16.2%
97.5%
Q3 24
-10.0%
-16.6%
Q2 24
-11.6%
-7.9%
Net Margin
ACVA
ACVA
CDNA
CDNA
Q1 26
2.4%
Q4 25
-3.8%
Q3 25
-12.3%
1.7%
Q2 25
-3.8%
-9.9%
Q1 25
-8.1%
-12.2%
Q4 24
101.3%
Q3 24
-9.4%
-12.8%
Q2 24
-10.6%
-5.0%
EPS (diluted)
ACVA
ACVA
CDNA
CDNA
Q1 26
$0.05
Q4 25
$-0.12
$-0.08
Q3 25
$-0.14
$0.03
Q2 25
$-0.04
$-0.16
Q1 25
$-0.09
$-0.19
Q4 24
$-0.15
$1.60
Q3 24
$-0.10
$-0.20
Q2 24
$-0.10
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACVA
ACVA
CDNA
CDNA
Cash + ST InvestmentsLiquidity on hand
$271.5M
$77.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$429.7M
Total Assets
$1.1B
$411.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACVA
ACVA
CDNA
CDNA
Q1 26
$77.9M
Q4 25
$271.5M
$177.2M
Q3 25
$265.3M
$194.2M
Q2 25
$258.4M
$186.3M
Q1 25
$291.9M
$230.9M
Q4 24
$224.1M
$260.7M
Q3 24
$252.5M
$240.9M
Q2 24
$215.0M
$228.9M
Total Debt
ACVA
ACVA
CDNA
CDNA
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$0
Q2 24
$0
Stockholders' Equity
ACVA
ACVA
CDNA
CDNA
Q1 26
Q4 25
$429.7M
$303.1M
Q3 25
$434.4M
$311.1M
Q2 25
$448.8M
$327.4M
Q1 25
$439.6M
$379.3M
Q4 24
$440.0M
$378.4M
Q3 24
$456.2M
$273.2M
Q2 24
$457.6M
$264.7M
Total Assets
ACVA
ACVA
CDNA
CDNA
Q1 26
$411.1M
Q4 25
$1.1B
$413.2M
Q3 25
$1.2B
$432.3M
Q2 25
$1.1B
$444.3M
Q1 25
$1.2B
$489.6M
Q4 24
$984.1M
$491.1M
Q3 24
$1.0B
$477.0M
Q2 24
$1.0B
$466.8M
Debt / Equity
ACVA
ACVA
CDNA
CDNA
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.00×
Q2 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACVA
ACVA
CDNA
CDNA
Operating Cash FlowLast quarter
$-12.4M
$4.3M
Free Cash FlowOCF − Capex
$-14.7M
$514.0K
FCF MarginFCF / Revenue
-8.0%
0.4%
Capex IntensityCapex / Revenue
1.2%
Cash ConversionOCF / Net Profit
1.54×
TTM Free Cash FlowTrailing 4 quarters
$69.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACVA
ACVA
CDNA
CDNA
Q1 26
$4.3M
Q4 25
$-12.4M
$21.4M
Q3 25
$10.3M
$37.4M
Q2 25
$13.7M
$9.9M
Q1 25
$66.6M
$-26.6M
Q4 24
$-3.2M
$21.9M
Q3 24
$21.1M
$12.5M
Q2 24
$4.5M
$18.9M
Free Cash Flow
ACVA
ACVA
CDNA
CDNA
Q1 26
$514.0K
Q4 25
$-14.7M
Q3 25
$7.7M
Q2 25
$10.9M
Q1 25
$65.3M
Q4 24
$-3.9M
Q3 24
$20.2M
Q2 24
$2.7M
FCF Margin
ACVA
ACVA
CDNA
CDNA
Q1 26
0.4%
Q4 25
-8.0%
Q3 25
3.8%
Q2 25
5.6%
Q1 25
35.7%
Q4 24
-2.5%
Q3 24
11.8%
Q2 24
1.7%
Capex Intensity
ACVA
ACVA
CDNA
CDNA
Q1 26
Q4 25
1.2%
Q3 25
1.3%
Q2 25
1.5%
Q1 25
0.7%
Q4 24
0.4%
Q3 24
0.6%
Q2 24
1.1%
Cash Conversion
ACVA
ACVA
CDNA
CDNA
Q1 26
1.54×
Q4 25
Q3 25
22.30×
Q2 25
Q1 25
Q4 24
0.25×
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACVA
ACVA

Auction Marketplace Revenue$77.6M42%
Other Marketplace Revenue$72.4M39%
Customer Assurance$24.1M13%
Data Services Revenue$9.4M5%

CDNA
CDNA

Financial Results Total$85.0M72%
Patient and digital solutions revenue$16.0M14%
Product revenue$10.3M9%
Other$6.4M5%

Related Comparisons